samedan logo
 
 
spacer
home > pmps > autumn 2021 > new aseptic containment approaches for parenteral production
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

New Aseptic Containment Approaches for Parenteral Production



The global injectables sector is growing fast. Recent estimates suggest it will be worth $624.5 billion worldwide by the end of 2021 – doubling in size since 2016 (1).

The reasons for this boom are twofold. The rise of biopharma to treat serious chronic conditions is partly responsible, with global sales of biopharmaceutical treatments hitting an all-time high of $300 billion in 2020 (2). In addition, the ongoing mass vaccination programme to bring the COVID-19 pandemic to an end has been a major contributor to high parenteral demand. According to IQVIA, global spending on the COVID-19 vaccine alone is expected to total $53 billion this year and $51 billion in 2022 (3).

Both biopharmaceutical therapies and vaccines, which are themselves biological, tend to require parenteral administration, to protect their active ingredients from damage via the oral route. As such, as demand for biologic and vaccine manufacturing grows, so too does demand for injectables.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christian Dunne is Head of Sterile Solutions at ChargePoint Technology for sterile containment solutions. For the past 20 years Christian has been creating innovative solutions for the pharmaceutical, biotech, cell therapy, and fine chemical industries to overcome high potency containment and aseptic processing challenges. His technical expertise spans high containment isolators, Grade A (ISO 5) sampling, and dispensing facilities, together with R&D and production filling line restricted access barrier systems and isolators.

Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLI® (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement